Cell cycle regulation of the G0/G1 transition in 5-fluorouracil-sensitive and -resistant human colon cancer cell lines

Cancer Journal

Volumn 6, Issue 4, 2000, Pages 234-242

  McGinn, C J ^a   Pestalozzi, B C ^a   Drake, J C ^a   Glennon, M C ^a   Kunugi, K ^a   Otterson, G ^a   Allegra, C J ^a   Johnston, P G ^a   Kinsella, T J ^a  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

Cell cycle; Colon cancer; Fluorouracil; G0 phase; G1 phase

Indexed keywords

FLOXURIDINE; FLOXURIDINE DERIVATIVE; FLOXURIDINE PHOSPHATE; FLUOROURACIL;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER CELL; CANCER SURVIVAL; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL GROWTH; CELL LINE; CELL POPULATION; CELL PROLIFERATION; COLON CANCER; DRUG SENSITIVITY; GENE AMPLIFICATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

ANTIMETABOLITES, ANTINEOPLASTIC; CELL CULTURE; CELL CYCLE; COLONIC NEOPLASMS; CYCLINS; DRUG RESISTANCE, NEOPLASM; FLUOROURACIL; HUMAN; KI-67 ANTIGEN; KINETICS; PHOSPHORYLATION; PROTEIN P16; RETINOBLASTOMA PROTEIN; SUPPORT, U.S. GOV'T, P.H.S.; THYMIDYLATE SYNTHASE; TUMOR CELLS, CULTURED;

EID: 0033791891     PISSN: 15289117     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Fluorouracil: Biochemistry and pharmacology
2. Thymidylate synthase gene amplification in a colon tumor resistant to fluoropyrimidine chemotherapy
3. Immunological quantitation of thymidylate synthase using the monoclonal antibody TS 106 in 5-fluorouracil-sensitive and -resistant human cancer cell lines
4. Thymidylate synthase gene amplification in human colon cancer cell lines resistant to 5-fluorouracil
5. In vivo kinetics of thymidylate synthetase inhibition of 5-fluorouracil-sensitive and -resistant murine colon adenocarcinomas
6. Fluorouracil and high-dose leucovorin in previously treated patients with metastatic breast cancer
7. Interaction of gamma interferon and 5-fluorouracil in the H630 human colon carcinoma cell line
8. Regulation of thymidylate synthase in human colon cancer cells treated with 5-fluorouracil and interferon-gamma
9. Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors
10. Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin
11. Increased thymidylate synthase gene expression in liver metastases from colorectal carcinoma: Implications for chemotherapeutic options and survival Cancer J Sci Am
12. Colorectal liver metastasis thymidylate synthase staining correlates with response to hepatic arterial floxuridine
13. The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer
14. p53 and thymidylate synthase expression in untreated stage II colon cancer: Associations with recurrence, survival, and site
15. Increased thymidylate synthase protein levels are principally associated with proliferation but not cell cycle phase in asynchronous human cancer cells
16. The role for translational control of the cell cycle
17. Regulation of p53 expression by thymidylate synthase
18. Thymidylate synthase binds to c-myc RNA in human colon cancer cells and in vitro
19. Characteristics of cell lines established from human colorectal carcinoma
20. Production and characterization of monoclonal antibodies that localize human thymidylate synthase in the cytoplasm of human cells and tissue
21. Biochemical determinants of tumor sensitivity to 5-fluorouracil: Ultrasensitive methods for the determination of 5-fluoro-2'-deoxyuridylate, 2'-deoxyuridylate, and thymidylate synthetase
22. An isotopic assay for thymidylate synthetase
23. Supravital cell staining with Hoechst 33342 and DiOC5(3)
24. Identification of proliferating cell by Ki-67 antibody
25. Synchronization of tumor and normal cells from G1 to multiple cell cycles by lovastatin
26. The thymidylate synthase inhibitor, ICI D1694, overcomes translational detainment of the enzyme
27. Catalytic function of thymidylate synthase is confined to S phase due to its association with replitase
28. Regulation of thymidylate synthetase in mouse leukemia cells (L1210)
29. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67
30. Thymidylate synthase activity in cultured mammalian cells
31. Regulation of thymidylate synthase activity in cultured mammalian cells
32. The retinoblastoma protein and cell cycle control
33. The retinoblastoma susceptibility gene product ungergoes cell cycle-dependent dephosphorylation and binding to and release from SV40 large T
34. The retinoblastoma-susceptibility gene product becomes phosphorylated in multiple stages during cell cycle entry and progression
35. The E2F transcription factor is a cellular target for the RB protein
36. Cellular targets for activation by the E2F1 transcription factor include DNA systhesis- and G1/ S-regulatory genes
37. Cyclins and cancer. II: Cyclin D and CDK inhibitors come of age
38. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4
39. Transcriptional repression of the D-type cyclin-dependent kinase inhibitor P16 by the retinoblastoma susceptibility gene product pRb
40. Differential expression and cell cycle regulation of the cyclin-dependent kinase 4 inhibitor p16(Ink4)
41. Evidence for different modes of action of cyclin-dependent kinase inhibitors: p15 and p16 bind to kinases, p21 and p27 bind to cyclins
42. p21 Is a universal inhibitor of cyclin kinases
43. p53-Dependent and independent expression of p21 during cell growth, differentiation, and DNA damage
44. Cloning of senescent cell-derived inhibors of DNA synthesis using an expression screen
45. p53-Independent expression of p21(CIP1) in muscle and other terminally differentiating cells
46. Cell cycle expression and p53 regulation of the cyclin-dependent kinase inhibitor p21
47. Induction of WAF1/CIP1 by a p53-independent pathway